TC BioPharm (Holdings) plc Overview
Pro stress-test →TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. The company develops allogeneic gamma-delta T cell platform therapies and owns manufacturing infrastructure to maintain cost and quality controls.
Strategic Profile
Pro stress-test →TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line—Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Competitive Landscape
Pro stress-test →TC BioPharm competes in the gamma-delta T cell immunotherapy space against established cell therapy programs at larger pharma companies and specialized biotech firms. Competitors include programs from Celldex Therapeutics, Kiadis Pharma, and other cell therapy platforms. The company's advantage lies in proprietary allogeneic gamma-delta platform and frozen product technology (CryoTC), but faces competitive pressure from CAR-T and CAR-NK therapies dominating cell therapy investment landscape.
Industry Context
TC BioPharm (Holdings) plc operates in Allogeneic cell therapy for oncology.
Key facts
Headquarters: Glasgow, UK · Market cap: N/A